[1]Galluzzi L,Senovilla L,Vitale I,et al. Molecular mecha-nisms of cisplatin resistance [J]．Oncogene,2012,31(15):1869-1883.
[2] Joo WD,Visintin I,Mor G． Targeted cancer therapy-are the days ofsystemic chemotherapy numbered? [J]． Maturitas,2013,76 ( 4) :308-314
[3]Mok TS,W u YL,Thongprasert S,et a1．Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]．N Engl J Med,2009,361(10)：947—957
[4]Mitsudomi T,Morita S,Yatabe Y,et a1．Gefitinib versuscisplatin plus docetaxel in patients with non—sm all-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405)：an open label,randomised phase 3 trial[J]．Lancet Oneol,2010,11(2)：121—128．
[5]Yang PC,Shi Y,Au js,et a1．Molecular epidemiological prospective study of EGFR mutations from Asian pa—tients(pts)with advanced lung adenocarcinoma(PI0一NEER)[J]．J CLin Oncol,2012,15(supp1)：1 534．
[6]Tomizawa Y,Fujita Y,Tamura A,etal. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy[J]．Lung Cancer,2010,68(2)：269-272
[7]Camidge DR,Bang Y,Kwak EL,et a1．Progression-freesurvival(PFS)from a phase I study of crizotinib (PF-02341066) in patients with ALK— positive non-smallcell lung cancer(NSCLC)[J]．J Clin Oncol,2011,29(Supp1.1)：S2 501．
[8]Solomon BJ,Mok T,Kim DW,etal．First—line crizotinibversus chemotherapy in ALK—positive lung cancer[J]．N Engl J Med,2014,371(23)：2167-2177．
[9]kwak EL,Bang YJ,Camidge DR,etal. Anaplastic lymphoma kinase inhibition in non-smal-cell lung cancer[J].N Engl J Med,2010,363(18): 1693-1703.DOI:10.1056/NEJMoa1006448.
[10]Camidge DR,Bang YJ,Kwak EL,etal.Activity and safety of crizotinib in patients with ALK-positivenon-small-cell lung cancer:update results from a phase 1 study[J].Lancet Oncol,2012,13(10):1011-1019.DOI:10.1016/S1470-2045(12)70344-3.
[11]Horn L,Pao W ．EM L4一ALK ：honing in on a new target in non-small—cell lung cancer[J]．J Clin Oncol,2009,27 (26)：4 232-4 235．
[12]Katzel J A, Fanucchi MP, Li Z. Recent advances of novel targetedtherapy in non- small cell lung cancer[J]. J Hematol Oncol,2009, 6(21): 2.doi:10. 1186/1756-8722-2-2.
[13] Shaw A T, Yeap B Y, Solomon B J,et al. Effect of crizotinib onoverall survival in patients with advanced non-small-cell lungcancer harbouring ALK gene rearrangement: a retrospectiveanalysis[J]. Lancet Oncol, 2011, 12(11) : 1004-1012. doi:10.1016/S1470-2045(11)70232-7.
[14] Reinmuth N,Reck M,Grohe C.Anti-angiogenic Strategy: TherapyOptimization of Non-squamous Non-small Cell Lung Carcinoma[J].Pneumologie,2014,68(12) :793-798.doi:10.1055/s-0034-1390807.
[15] Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med,2009, 361(10) : 958-967. doi: 10. 1056/NEJMoa0904554.
[16] VAN DEＲ BＲUGGEN P,TＲAVEＲSAＲI C,CHOMEZ P,et al． A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma[J]． Science,1991,254(5038):1643
[17] WEON JL,POTTS PR．The MAGE protein family and cancer[J]．Curr Opin Cell Biol,2015,37:1
[18] SINGH V,BＲADDICK D．Ｒecent advances and versatility of MAGE towards industrial applications[J]． Syst Synth Bi-ol,2015,9(Suppl 1):1
[19] 夏小军.裴正学教授治疗白血病经验介绍[J]．新中医,2006,38( 1) :21-23．
[20]张旭霞,山广志．参莲胶囊合消癌平注射液治晚期非小细胞肺癌 40 例[J]．江西中医药,2011,42 ( 8) : 27 －28．
[21]王云启,梁慧.肺康复方改善中晚期非小细胞肺癌患者生活质量的临床研究[J].湖南中医药大学学报,2014,34(8):32 －35.
[22] 庄毅.康艾注射液治疗中老年晚期非小细胞肺癌 40 例疗效观察[J].世界中医药,2015,10(11):1723 －1725.
[23]张翀．邱幸凡教授治疗肺癌的经验[J]．世界中西医结合杂志,2010,5( 10) : 839－840．
[24]曹爱玲．吴承玉治疗肺癌经验[J]．山东中医杂志,2015,34( 12) : 954 －956．
|
